

AMARIN CORP PLC\UK  
Form 424B3  
December 09, 2010

Filed Pursuant to Rule 424(b)(3)  
Registration No. 333-163704

**PROSPECTUS SUPPLEMENT**

(To prospectus dated November 10, 2010)

**119,512,556 Ordinary Shares**

**AMARIN CORPORATION PLC**

This prospectus supplement (this Supplement) supplements and amends the prospectus included in the post-effective amendment No. 1 to our registration statement (File No. 333-163704) filed on November 10, 2010 and declared effective by the U.S. Securities and Exchange Commission on November 23, 2010 (as so amended and supplemented, the Prospectus), which relates to the sale of up to 119,512,556 of our ordinary shares, par value £0.50 per share ( Ordinary Shares ), each represented by one American Depositary Share ( ADS ), of Amarin Corporation plc, by the selling shareholders named in the Prospectus or their transferees, pledgees, donees or other successors in interest. This Supplement does not relate to our issuance of additional Ordinary Shares or ADSs beyond the 119,512,556 originally covered by the Prospectus.

This Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus, which is to be delivered with this Supplement. This Supplement is qualified by reference to the Prospectus, except to the extent that the information in this Supplement updates and supersedes the information contained in the Prospectus.

Our ADSs are listed on the NASDAQ Capital Market, the principal trading market for our securities, under the symbol AMRN.

**INVESTING IN THESE SECURITIES INVOLVES RISKS. SEE RISK FACTORS BEGINNING ON PAGE 4 OF OUR ANNUAL REPORT ON FORM 20-F INCLUDED IN THE ABOVE-REFERENCED PROSPECTUS AS WELL AS THE RISK FACTORS AND OTHER INFORMATION CONTAINED IN DOCUMENTS WE FILE WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION AND WHICH ARE INCORPORATED BY REFERENCE IN THE PROSPECTUS TO READ ABOUT FACTORS YOU SHOULD CONSIDER BEFORE BUYING THESE SECURITIES.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this Supplement is truthful or complete. Any representation to the contrary is a criminal offense.**

The date of this prospectus supplement is December 9, 2010.

Edgar Filing: AMARIN CORP PLC\UK - Form 424B3

The information in the table appearing under the caption "Selling Shareholders" commencing on page 7 of the Prospectus is hereby supplemented and amended by adding the information below with respect to selling shareholders not previously listed in the Prospectus, and by superseding the information with respect to selling shareholders listed below as of or prior to the date of this Supplement.

The information set forth in the table below is current as of December 6, 2010. Since the date on which we were provided with the information regarding their security ownership in Amarin Corporation plc, selling shareholders may have acquired, sold, transferred or otherwise disposed of all or a portion of their securities. Accordingly, the information provided herein and in the Prospectus for any particular shareholder may understate or overstate, as the case may be, such shareholder's current ownership.

Selling Shareholder	Ordinary		Percentage of		
	Shares Owned	Ordinary	Ordinary	Ordinary	
	Prior to	Shares to be	Shares to be	Shares to be	
	Offering	owned	owned	owned	
	(Including	upon	upon	upon	
	Ordinary Shares	completion	completion	completion	
	underlying	of	of	of	
	warrants)	offering	offering	offering	
	Prior to	Shares to	Shares to	Shares to	
	Offering	be Offered	be Offered	be Offered	
	Percentage	Ordinary	Ordinary	Ordinary	
	of Ordinary	Shares	Shares	Shares	
	Owned	Owned	Owned	Owned	
	Shares	Prior to	Shares to	Shares to	
	Owned	Offering	be Offered	be Offered	
	Prior to	Shares to	Shares to	Shares to	
	Offering	be Offered	be Offered	be Offered	
	Percentage	Ordinary	Ordinary	Ordinary	
	of Ordinary	Shares	Shares	Shares	
	Owned	Prior to	Shares to	Shares to	
	Shares	Offering	be Offered	be Offered	
	Owned	Offering	be Offered	be Offered	
	Percentage	Ordinary	Ordinary	Ordinary	
	of Ordinary	Shares	Shares	Shares	
	Owned	Prior to	Shares to	Shares to	
	Shares	Offering	be Offered	be Offered	
	Owned	Offering	be Offered	be Offered	
	Percentage	Ordinary	Ordinary	Ordinary	
	of Ordinary	Shares	Shares	Shares	
	Owned	Prior to	Shares to	Shares to	
	Shares	Offering	be Offered	be Offered	
	Owned	Offering	be Offered	be Offered	
Biomedical Offshore Value Fund, L.P. (4)(17)(20)					
c/o Great Point Partners, LLC					
165 Mason Street					
3 <sup>rd</sup> Floor	3,145,000	3.13%	3,145,000	0	0%
Greenwich, CT 06830					
Biomedical Value Fund, L.P. (4)(15)(18)(20)					
c/o Great Point Partners, LLC					
165 Mason Street					
3 <sup>rd</sup> Floor	4,789,739	4.74%	4,789,739	0	0%
Greenwich, CT 06830					
Biomedical Institutional Value Fund, L.P. (4)(15)(19)(20)					
c/o Great Point Partners, LLC					
165 Mason Street					
3 <sup>rd</sup> Floor	1,258,539	1.26%	1,258,539	0	0%

Edgar Filing: AMARIN CORP PLC\UK - Form 424B3

Greenwich, CT 06830

OTA LLC (4)(17)(18)(19)(20)

One Manhattanville Road

1,400,000	1.38%	1,400,000	0	0%
-----------	-------	-----------	---	----

Purchase, NY 10577

- (2) An investor in the May 2008 Financing
- (4) Pursuant to the terms of the 2009 Private Placement, the selling stockholder has certain registration rights and rights of first refusal to purchase up to its pro rata share of any offering by the Company of Ordinary Shares or any other class or series of its capital stock.
- (15) Biomedical Value Fund, L.P. transferred to Biomedical Institutional Value Fund, L.P. 963,270 Ordinary Shares and warrants to purchase 487,537 Ordinary Shares.
- (17) Biomedical Offshore Value Fund, L.P. transferred to OTA LLC warrants to purchase 476,000 Ordinary Shares.
- (18) Biomedical Value Fund, L.P. transferred to OTA LLC warrants to purchase 731,732 Ordinary Shares.
- (19) Biomedical Institutional Value Fund, L.P. transferred to OTA LLC warrants to purchase 192,268 Ordinary Shares.
- (20) Based on the number of Ordinary Shares outstanding on December 6, 2010, and calculated in accordance with Rule 13d-3 of the Exchange Act.